Arkansas, Louisiana and Mississippi Seniors Get Access to New Therapy to Heal Difficult Chronic Ulcers
TheraSkin® a biologically active real skin wound therapy, is now covered for Medicare Beneficiaries in Arkansas, Louisiana and Mississippi. Clinical results are excellent, and demonstrate the potential to save many Seniors from life-threatening lower limb amputations. Estimated to save healthcare in the US more than one billion dollars over next decade
Newport News, VA (PRWEB) July 23, 2011
Soluble Systems, LLC announced today that Pinnacle Business Solutions, Inc., the Medicare Part A Fiscal Intermediary for Arkansas, Louisiana and Mississippi and Part B Carrier from Arkansas and Louisiana,, has decided to provide coverage for TheraSkin in the treatment of poorly healing diabetic foot ulcers and venous leg ulcers.
This is good news for the 1.7 million Medicare-eligible beneficiaries and very good news indeed for the estimated 27% who have diabetes and are likely to develop diabetic foot ulcers and venous leg ulcers. These ulcers are often extremely difficult to heal and, when all else fails, are involved in nearly two-thirds of all non-traumatic lower limb amputations each year.
TheraSkin, a real skin wound therapy, offers real help. A recently published peer-reviewed research study involving 188 patients shows that TheraSkin closed over 60% of these “non-healing” ulcers in 12 weeks, typically with five or fewer applications.
Importantly, the coverage of TheraSkin provides health care practitioners and patients a new weapon in the battle to effectively treat chronic wounds and reduce health care costs. TheraSkin is good for the healthcare pocket book. Because the product is 50 to 70 percent less expensive than substitute products, the Medicare program can potentially save more than a billion dollars over the next decade.
TheraSkin is also good for the patient’s pocket book. The Part B co-pay for alternative products can run as high as $2,400. Because TheraSkin is less expensive per unit and fewer applications are generally required, the Part B co-pay can be expected to be $750 or less.
What is TheraSkin? TheraSkin® is a biologically active cryopreserved human skin allograft for non-responsive chronic wounds. TheraSkin’s fully developed extracellular matrix (ECM) and living cells provide an “at-ready” supply of human growth factors, cytokines and collagen to jumpstart wound healing. TheraSkin is a clinically and cost effective alternative to bioengineered skin substitutes (BSS) currently used to help heal chronic wounds. Like BSS, TheraSkin provides necessary growth factors and cytokines. Unlike BSS, TheraSkin provides a large quantity of essential human collagens in appropriate ratios to support healing.
Soluble Systems, LLC has partnered with the Skin and Wound Allograft Institute (SWAI), a wholly owned subsidiary of LifeNet Health, to bring TheraSkin to market. LifeNet Health is the world’s largest provider of bio-implants and organs for transplantation.
More About Soluble Systems, LLC: Soluble Systems, LLC is the manufacturer and/or distributor of a line of advanced wound care products. In addition to TheraSkin®, the company markets TheraGauze®. Patented Skin Moisture Rebalancing Technology (SMRT) enables TheraGauze to regulate moisture differentially across a wound bed and to aid in wound healing without maceration. TheraGauze is manufactured in a certified clean room environment pursuant to FDA regulations in Hampton, Virginia. Corporate offices are located in Newport News, Virginia. For additional information about Soluble Systems, please visit http://www.solublesystems.com.
More About SWAI: SWAI, the Skin and Wound Allograft Institute, is a wholly owned non-profit subsidiary of LifeNet Health. It was formed in 2008 to provide high quality bio-implants for patients with acute burns, traumatic injuries and chronic wounds. LifeNet Health helps to save lives and restore health for thousands of patients each year. We are the world’s most trusted provider of transplant solutions, from organ procurement to new innovations in bio-implant technologies and cellular therapies””a leader in the field of regenerative medicine, while always honoring the donors and healthcare professionals that allow the healing process. For additional information about SWAI, please visit http://www.SWAI.org.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2011/7/prweb8660688.htm